{"slideshow_credits": null, "snippet": "Some of the most influential medical groups in the nation are recommending that doctors weigh the costs, not just the effectiveness of treatments that they recommend for patients.", "abstract": "Some of most influential medical groups in nation are recommending that doctors weigh costs, not just effectiveness of treatments, as they make decisions about patient care; shift suggests doctors, who say they can no longer ignore rising prices of health care, are starting to redefine their roles, and could result in them choosing one drug over another for cost reasons.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/04/18/business/treatment-cost-could-influence-doctors-advice.html", "lead_paragraph": "Some of the most influential medical groups in the nation are recommending that doctors weigh the costs, not just the effectiveness of treatments that they recommend for patients.", "headline": {"main": "Cost of Treatment May Influence Doctors", "print_headline": "Treatment Cost Could Influence Doctors\u2019 Advice"}, "_id": "5350953e38f0d8777a368262", "word_count": "1241", "multimedia": [{"height": 126, "url": "images/2014/04/18/business/DOCS1/DOCS1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/04/18/business/DOCS1/DOCS1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 1144, "url": "images/2014/04/18/business/DOCS1/DOCS1-articleLarge.jpg", "legacy": {"xlarge": "images/2014/04/18/business/DOCS1/DOCS1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "1144"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/04/18/business/DOCS2/DOCS2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/04/18/business/DOCS2/DOCS2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-04-18T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Avastin (Drug)", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Medicare", "name": "subject", "is_major": "N", "rank": "9"}, {"value": "American Society of Clinical Oncology", "name": "organizations", "is_major": "N", "rank": "7"}, {"value": "American Heart Assn", "name": "organizations", "is_major": "N", "rank": "6"}, {"value": "Doctors", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "American College of Cardiology", "name": "organizations", "is_major": "N", "rank": "8"}, {"value": "Health Insurance and Managed Care", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Lucentis (Drug)", "name": "subject", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}